HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China January 23, 2023
HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on n ...